• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Addition of indoximod to taxane chemotherapy does not improve survival in patients with metastatic breast cancer

byTeddy Guo
December 9, 2020
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer

Tags: docetaxelindoximodmetastatic breast cancerpaclitaxeltaxane chemotherapy
Previous Post

Improved contraception use with progestogen-only pill and rapid access vs emergency contraception

Next Post

#VisualAbstract: Acamprosate found an effective and tolerable interventions for alcohol dependence

RelatedReports

Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

July 24, 2025
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Chronic Disease

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

July 23, 2025
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
StudyGraphics

#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer

February 7, 2025
#VisualAbstract: Fruquintinib Plus Paclitaxel Improved Progression-Free Survival in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
StudyGraphics

#VisualAbstract: Fruquintinib Plus Paclitaxel Improved Progression-Free Survival in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

June 21, 2024
Next Post
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure

#VisualAbstract: Acamprosate found an effective and tolerable interventions for alcohol dependence

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

Major birth defects and chromosomal abnormalities significantly associated with increased cancer risk

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

Weekly selinexor, bortezomib, and dexamethasone demonstrates improved survival in treatment-refractory multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind September 15, 2025
  • Effectiveness and user experiences of a valgus brace in patients with knee osteoarthritis: A mixed-method randomised controlled trial
  • Artificial intelligence accelerates drug discovery and reduces animal testing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.